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ABSTRACT
Aims: What is the evidence base for the effectiveness of interventions to reduce tuberculosis (TB)
incidence in countries which have low TB incidence?
Methods: We conducted a systematic review of interventions for TB control and prevention relevant to
low TB incidence settings (<10 cases per 100000 population). Our analysis was stratified according to
“direct” or “indirect” effects on TB incidence. Review quality was assessed using AMSTAR2 criteria. We
summarised the strength of review level evidence for interventions as “sufficient”, “tentative”, “insufficient”
or “no” using a framework based on the consistency of evidence within and between reviews.
Results: We found sufficient review level evidence for direct effects on TB incidence/case prevention of
vaccination and treatment of latent TB infection. We also found sufficient evidence of beneficial indirect
effects attributable to drug susceptibility testing and adverse indirect effects (measured as sub-optimal
treatment outcomes) in relation to use of standardised first-line drug regimens for isoniazid-resistant TB
and intermittent dosing regimens. We found insufficient review level evidence for direct or indirect effects
of interventions in other areas, including screening, adherence, multidrug-resistant TB, and healthcare-
associated infection.
Discussion: Our review has shown a need for stronger evidence to support expert opinion and country
experience when formulating TB control policy.
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Introduction
Projected trends indicate that a substantial strengthening of efforts to reduce tuberculosis (TB) incidence is
needed if the World Health Organization (WHO) End TB strategy is to be met in countries of low TB
incidence [1]. Whilst frameworks to accelerate the reduction in TB incidence can be reached by expert
consensus [2, 3], it is fundamental that these are underpinned by a robust and up-to-date evidence base
for the effectiveness of specific interventions. Such an evidence base also allows for harmonisation of
best-practice approaches to TB control between countries which have shared (or open) borders, such as
across the European Union/European Economic Area (EU/EEA) [4–6].
Systematic reviews are a recognised method for compiling and assessing the findings of multiple systematic
reviews into one accessible and usable summary of the evidence base [7, 8]. The objective of the present
review was: 1) to identify systematic reviews of interventions to reduce TB incidence and prevent TB cases in
settings of low TB incidence; 2) to assess the quality of the reviews in relation to direct and indirect effects of
the interventions on TB incidence; and 3) to summarise the overall strength of evidence for each reviewed
intervention. We focused on reviews of interventions for which reduction in TB incidence and prevention of
TB cases was a measurable outcome, but our broad definition of “intervention” also encompassed approaches
to TB diagnosis and treatment which could have an indirect impact on TB incidence. The overall aim of the
review was to provide an evidence base to inform the development and implementation of national TB plans.
Methods
This systematic review was conducted as part of the European Commission funded E-DETECT TB (Early
Detection and Integrated Management of Tuberculosis in Europe) project, which aims to improve TB
control efforts across Europe through translational research designed to reach high-risk groups in EU/EEA
countries, as well as the development of a practical evidence-based toolkit to support development and
implementation of national TB plans [9, 10]. The review protocol was defined in advance and registered
with PROSPERO (www.crd.york.ac.uk/prospero/ CRD42017060096).
Inclusion and exclusion criteria
Systematic reviews of interventions for TB control and prevention in settings of low TB incidence (<10
cases per 100000 population) were eligible [11]. We defined “intervention” as any population level, public
health or clinical (at primary, secondary or tertiary level) activity which prevents further cases of active TB
or latent TB infection (LTBI), and which has the potential to reduce the incidence of TB at local, regional
or national level. This broad definition of “intervention” would include: actions specifically designed for/
targeted at TB control/case prevention; clinical approaches, such as different diagnostic methods and drug
regimens; areas of activity defined by particular patient groups, e.g. HIV co-infected, multidrug-resistant
(MDR)-TB, vulnerable groups, pregnant women, or settings such as healthcare facilities and prisons; and
areas of action defined by level of intervention, e.g. social and healthcare systems. Our analysis was
stratified by type of effect, distinguishing reviews of interventions which reported a quantifiable
“direct effect” from those which had an “indirect effect” on reducing TB incidence or preventing TB cases
(table 1). Pre-specified reasons for excluding reviews were: not a systematic review; no intervention
evaluated; no direct or indirect effect in preventing TB cases/reducing TB incidence; and economic
evaluation only (see Appendix S2 for inclusion checklist). We did not exclude systematic reviews which
included studies set in countries with high TB incidence if the review included at least one study in a low
TB-incidence setting. As an adjunct to our main analysis, we included reviews of “risk factors” which
could modify the effects of interventions or which, if targeted in a hypothetical intervention, could lead to
a reduction in TB incidence. Our aim with regard to risk factors was to highlight possible future areas for
intervention, particularly those which currently fall outside conventional TB-focused public health or
clinical approaches to reducing TB incidence or which could reduce or enhance the effectiveness of
conventional interventions.
TABLE 1 Stratification of systematic reviews of interventions
Direct effect
Evidence that intervention has a direct effect in controlling or preventing TB, i.e. preventing cases or
reducing incidence, reported as a primary or secondary outcome of the review
Indirect effect
No direct effect reported, but intervention has a plausible indirect effect in preventing TB cases or
reducing TB incidence, for example via improvements in diagnosis, detection, treatment outcomes and
reductions in transmission and resistance
TB: tuberculosis.
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Search methods for identification of reviews
The following databases were searched from inception to May 2017: MEDLINE, EMBASE, CINAHL,
Scopus, Global Health, Trip, Cochrane Library, Social Policy and Practice, HMIC (Health Management
Information Consortium), DoPHER (Database of Promoting Health Effectiveness Reviews), Health
Systems Evidence and National Guideline Clearinghouse. In addition, the PROSPERO systematic reviews
register and the International Journal of Tuberculosis and Lung Disease were searched within the same
period. Full search strategies are shown in Appendix S1. In brief, we used a search filter developed by LEE
et al. [12], combined with MeSH and title word terms for tuberculosis, mycobacterium and TB. To search
databases of reviews, health evidence or guidelines, we simply used terms for tuberculosis/TB. No language
or date restrictions were imposed.
Selection of reviews
Citations identified by the search were imported into EndNote (EndNote X8; Clarivate Analytics, Boston,
MA, USA) for de-duplication, and then imported into to EPPI-Reviewer 4 (EPPI-Centre Software, Social
Science Research Unit, UCL Institute of Education, London, UK) for further de-duplication and for
screening. Two reviewers screened references by title and abstract, with any disagreements resolved by
discussion with a third reviewer. Full texts of all articles identified in the second screen by title and
abstract were retrieved. The full texts of retrieved articles were screened for final inclusion independently
and in parallel by two reviewers, with any disagreements resolved by discussion with a third reviewer.
When several versions of reviews were identified, only the most recent was included. If there was more
than one publication of an identical review (e.g. a Cochrane review and a journal version including the
same papers), the reference with the most detail was included.
Data extraction and management
The following data were extracted: bibliographic details (author, year, title); category (area of intervention);
type of intervention; outcomes reported; number of included studies and/or participants; key findings; and
authors’ conclusions. Areas and types of intervention were not pre-defined, but emerged thematically and
were rationalised during the screening process.
Assessment of methodological quality of the systematic reviews
Quality of included reviews was assessed using the AMSTAR2 tool, a 16-item measurement tool
specifically used to assess systematic reviews that include randomised or non-randomised studies of
healthcare interventions (or both) [13]. Five domains from the 16 items were considered to be “critical”: 1)
the adequacy of the literature search; 2) assessment of risk of bias in included studies; 3) appropriate
meta-analytical methods; 4) consideration of risk of bias in interpreting the results of the review; and 5)
assessment of presence and impact of publication (small study) bias. The other 10 domains were
considered to be “non-critical”. Confidence in the results of the review was classified as “high” if it had <4
non-critical and no critical weaknesses, “moderate” if ⩾4 non-critical but no critical weaknesses, “low” if
one critical weakness, and “very low” if ⩾2 critical weaknesses [14]. Reviews of “risk factors” were not
assessed for methodological quality.
Data analysis
Included reviews (direct or indirect effects) were summarised descriptively by category (area) of
intervention, including the number and type of primary studies (randomised controlled trials (RCTs) or
“other” studies, meaning non-randomised and observational studies). Areas of intervention were not
specified a priori, but emerged by inspection of the topics covered by the included reviews, with the aim of
defining areas which had the least amount of overlap. Reviews were categorised into either high-quality
“core” reviews (high confidence in the results of the review according to AMSTAR2 criteria) which formed
the basis of evidence used to assess interventions, or “supplementary” reviews which were not considered
to be of sufficient quality to rely on the authors’ conclusions but which provided additional information to
complement the core reviews. For each type of intervention, we extracted information on the review
authors’ assessment of the evidence and the design and findings of primary studies included in that
review. The overall level of evidence in support of, or discounting, the effectiveness of an intervention was
classified as “sufficient”, “tentative”, “insufficient” or “no” review level evidence, using a framework based
on the consistency of evidence within and between reviews, and concluding statements made by the
authors (table 2).
Results
We identified 11578 references, including 1654 from MEDLINE, 2796 from EMBASE, 250 from CINAHL,
2949 from Scopus, 1059 from Global Health, 2040 from Trip, and 92 from Cochrane. Of these, 7499 were
removed by de-duplication, leaving 4079 to be screened by title and abstract. Screening by title and
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abstract eliminated 3813 references, leaving 266 references for full text review (figure 1). Of these, 187 were
included, covering 13 areas of intervention (table 3) and comprising 45 reviews of interventions reporting
a direct effect, 113 an indirect effect, and 29 describing risk or contextual factors (Appendix S3). Quality
assessment rated direct effect (17 (37.8%) out of 45) and indirect effect (28 (24.8%) out of 113) reviews as
high-quality core reviews (table 4 and Appendix S4). A full textual data synthesis for each category of
intervention stratified by effect is provided in Appendix S5. The results below summarise the overall
(review level) evidence in support of, or discounting, the effectiveness of interventions.
Sufficient review level evidence for direct or indirect effects of interventions
Vaccination
There was a sufficient level of evidence from systematic reviews to support the use of bacille Calmette–
Guerin (BCG) vaccination, with evidence of protective effects against pulmonary and extrapulmonary TB
of up to 10 years’ duration. Vaccine efficacy varied by age and tuberculin sensitivity status at time of
vaccination, and was greatest when comparing naïve individuals with naïve unvaccinated individuals.
These results derived from four core reviews [15–18], the largest of which included 21 RCTs and 111
other studies, covering all age groups [15]. An update of this review, but restricted to neonatal and infant
vaccination, found no additional studies [16]. These last two reviews recommended selective BCG
vaccination, for example, of infants born to immigrants from high TB-incidence countries or close
contacts of active TB cases, whilst acknowledging a lack of evidence for cost-effectiveness compared with
universal vaccination.
Diagnosis
Diagnostic accuracy of TB diagnostic tests in different patient groups is increasingly well-characterised.
There is insufficient review level evidence either to support or discount direct effects of interferon γ-release
assays (IGRAs) compared with tuberculin skin test (TST) in predicting which cases of LTBI would
progress to active TB, i.e. the two tests are similar in predictive value (high negative predictive value, low
positive predictive value). There is sufficient review level evidence of indirect effects on TB incidence of
performing molecular drug susceptibility testing. This assessment was based on three core reviews of
molecular drug susceptibility testing: 1) a UK HTA review of GenoType MTBDRplus (isoniazid (INH)
and rifampicin), INNO-LiPA Rif.TB (rifampicin) and Xpert MTB/RIF (rifampicin) [51]; 2) a Cochrane
review of the Xpert MTB/RIF assay [54]; and 3) a review of three commercial line probe assays, Hain
Genotype MTBDRplusV1, MTBDRplusV2 and Nipro NTM+MDRTB [52]. The conclusion of all three
reviews was that molecular tests had high sensitivity and specificity (regardless of HIV status) for
rifampicin and INH resistance, e.g. for rifampicin resistance detection Xpert MTB/RIF pooled sensitivity
and specificity were 95% and 98%, respectively [54].
TABLE 2 Framework to classify review level evidence
Sufficient review level evidence to either support or discount the effectiveness of an intervention
Clear and consistent statement from one or more core reviews based on multiple robust studies, or
Consistent evidence across multiple robust studies within one or more core reviews, in the absence of a
clear and consistent statement in the review(s)
Tentative review level evidence to either support or discount the effectiveness of an intervention
A cautious statement from one or more core reviews based on consistent evidence from a small number
of robust studies, or
Consistent evidence from a small number of robust studies or multiple weaker studies within one or
more core reviews, in the absence of a clear and consistent statement in the review(s), or
Conflicting evidence from one or more core reviews, with the stronger evidence weighted towards one
side (either supporting or discounting effectiveness) and a plausible reason for the conflict, or
Consistent evidence from multiple robust studies within one or more supplementary review, in the
absence of a core review
Insufficient review level evidence to either support or discount the effectiveness of an intervention
A statement of insufficient evidence from a core review, or
Insufficient evidence to either support or discount the effectiveness of an intervention (either because
there is too little evidence or the evidence is too weak), in the absence of a clear and consistent
statement of evidence from a core review(s), or
Anything less than consistent evidence from multiple robust studies within one or more supplementary
reviews.
No review level evidence
No core or supplementary reviews of the topic identified, possibly due to a lack of primary studies
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Treatment
A sufficient level of evidence for the relative effectiveness of different drug regimens in treating LTBI to
prevent progression to active TB was provided by four core reviews [63–66]. The largest and most recent
was a network meta-analysis based on 61 RCTs covering all age groups, which found evidence for the
efficacy and safety (compared to no treatment or placebo) of 6 months of INH monotherapy, 3–4 months
of rifampicin monotherapy, and combination therapies with 3–4 months of INH and rifampicin,
regardless of age and HIV status [66]. SHARMA et al. [64] (10 RCTs, all age groups) concluded that
shortened regimens using rifampicin alone had not demonstrated higher rates of active TB when
compared to longer INH regimens, probably with better treatment completion and fewer adverse events;
and that shortened combined regimens of rifampicin with INH offered no advantage over longer INH
regimens. The impact of LTBI treatment on TB incidence at population level has not been evaluated
because its overall effectiveness is entirely dependent on related interventions, particularly screening.
There is sufficient review level evidence of indirect effects via sub-optimal outcomes related to treatment
of INH-resistant TB with standardised regimens of first-line drugs, and three times weekly dosing
throughout therapy and twice weekly dosing in the continuation phase compared with daily therapy.
There is insufficient review level evidence for other treatment-related “interventions”, including therapeutic
drug monitoring, nutritional supplementation and smoking cessation. Whilst TB patients with diabetes
appear to have worse outcomes, there is currently no evidence base for changes to TB treatment regimens.
HIV/TB
There is sufficient review level evidence to support LTBI treatment and antiretroviral therapy (ART) to
prevent active TB in people infected with HIV, although this evidence derives mainly from studies in low-
or middle-income countries. Of the three core reviews: one reviewed LTBI treatment in HIV-positive
adults based on 12 RCTs, finding a reduced risk of active TB comparing various anti-TB drug regimens
with placebo, particularly among patients with a positive TST [115]; another review in HIV-positive
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FIGURE 1 Study selection (PRISMA flow diagram).
https://doi.org/10.1183/16000617.0107-2018 5
TUBERCULOSIS | S.M. COLLIN ET AL.
children also reported a marked reduction in risk of active TB, but based on a single RCT [116]; and a
review of ART for prevention of TB in adults based on three RCTs and eight other studies found a
substantial reduction in TB incidence [117].
Insufficient review level evidence for direct or indirect effects of interventions
Screening
Whilst migrants from high TB incidence countries often have a higher prevalence of active and latent TB
than the general population in low TB incidence countries, there was insufficient evidence from systematic
reviews to either support or discount the effectiveness of different screening approaches to prevent TB
cases, reducing TB incidence, reducing mortality or preventing transmission. Eight supplementary reviews
of migrant screening (two reviewing pre-entry screening/follow-up [32, 34], one point-of-entry screening
[42], four post-entry screening [33, 36–38] and one screening at all three points [45]) favoured pre- or
post-entry screening of migrants from high TB-incidence countries (based mainly on case yield and risk of
TB developing post-entry) compared with no screening, but none compared the effectiveness of different
approaches or provided conclusive evidence of cost-effectiveness. All eight reviews stressed the need for
comparative studies and improved longitudinal data collection.
TABLE 3 Specific interventions evaluated by included reviews (not an exhaustive list)
Intervention area Specific interventions evaluated by included reviews
Vaccination BCG vaccination: universal or selective (contacts and high-risk groups)
Screening Pre-, post- and point-of-arrival testing for active TB or LTBI in
migrants
Active case finding in primary care settings, and in high-risk and
vulnerable population groups
Diagnosis Diagnostic accuracy of TST versus IGRA
Drug susceptibility testing
Treatment Efficacy and safety of drug regimens for treating LTBI
Therapeutic drug monitoring
Nutritional supplementation
Diabetes
Adherence Directly observed treatment, incentives, lay healthcare workers and
reminder systems
HIV/TB Efficacy and safety of antiretroviral therapy for treating HIV and/or
drug regimens for treating LTBI
Diagnostic accuracy of TST versus IGRA
Drug susceptibility testing
Service integration
MDR-TB Efficacy and safety of drug regimens for treating MDR-TB
Efficacy and safety of drug regimens for preventing MDR-TB in
contacts of MDR-TB cases
Directly observed therapy and care models
Contacts and transmission Contact investigation
Whole genome sequencing
Air travel
Healthcare-associated infection Serial screening for TB in healthcare workers
Clinical prediction rules
Social support and vulnerable
groups
Socioeconomic and psychosocial support
Reaching vulnerable groups
Healthcare systems Integrated care models
Scaling up
Task shifting
Pregnancy and sex Efficacy and safety of drug regimens for treating active TB, LTBI and
MDR-TB
Sex-specific approaches to TB diagnosis and treatment
Prisons Isoniazid preventive therapy
Environment and behaviours Smoking, second-hand tobacco smoke and indoor air pollution
Alcohol
TB: tuberculosis; MDR-TB: multidrug-resistant TB; BCG: bacille Calmette–Guerin; LTBI: latent TB
infection; TST: tuberculin skin test; IGRA: interferon γ-release assay.
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TABLE 4 Studies included and excluded after full text review
Intervention area
Included reviews
Excluded
reviews
Full text
screen
total
Direct effects# Indirect effects# Risk factors
High Moderate Low Very low High Moderate Low Very low
Vaccination 4 [15–18] 0 1 [19] 8 [20–27] 0 0 0 0 0 4 17
Screening 0 0 3 [28–30] 0 1 [31] 0 4 [32–35] 10 [36–45] 0 11 30
Diagnosis 1 [46] 0 0 1 [47] 7 [48–54] 0 5 [55–59] 3 [60–62] 0 4 22
Treatment 4 [63–66] 1 [67] 0 3 [68–70] 9 [71–79] 0 4 [80–83] 4 [84–87] 2 [88, 89] 10 36
Adherence 1 [90] 0 0 0 8 [91–98] 0 2 [99–101] 12 [102–113] 1 [114] 5 30
HIV/TB 3 [115–117] 0 2 [118, 119] 4 [120–123] 1 [124] 0 2 [125, 126] 3 [127–129] 0 7 22
Multidrug-resistant TB 3 [130–132] 0 0 1 [133] 0 0 3 [134–136] 14 [137–150] 0 9 30
Contacts and transmission 0 0 0 0 0 1 [151] 2 [152, 153] 3 [154–156] 3 [157–159] 4 13
Healthcare-associated infection 0 0 0 1 [160] 1 [161] 0 1 [162] 4 [163–166] 4 [167–170] 9 17
Social support and vulnerable groups 1 [171] 0 0 1 [172] 1 [173] 0 0 1 [174] 0 1 5
Healthcare systems 0 0 0 0 0 0 1 [175] 4 [176–179] 2 [180, 181] 12 19
Pregnancy and sex 0 0 0 1 [182] 0 0 0 0 5 [183–187] 1 7
Prisons 0 0 0 1 [188] 0 0 0 1 [189] 1 [190] 1 4
Environment and behaviours 0 0 0 0 0 0 0 0 11 [191–201] 1 13
Subtotals 17 1 6 21 28 1 25 59 29 79 266
Direct effect: evidence that intervention has a direct effect in preventing cases or reducing incidence, reported as a primary or secondary outcome measure of the review; indirect effect:
intervention has a plausible indirect effect in preventing tuberculosis (TB) cases or reducing TB incidence, regardless of the outcome measures reported in the review; risk factors: no
intervention was evaluated but the review described risk (or contextual) factors which could modify the effects of interventions or which, if targeted in a hypothetical intervention, could
lead to a reduction in TB incidence. #: the AMSTAR2 criteria were used to categorise the included reviews as either “core” reviews (providing an evidence base for interventions) of high
quality or “supplementary” reviews (providing additional information) of moderate, low or very low quality.
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Adherence
There is insufficient review level evidence, particularly in high-income/low TB-incidence countries, to
support or discount direct or indirect effects of treatment adherence interventions to reduce the incidence
of active TB, including directly observed treatment (DOT), incentives, lay healthcare workers (HCWs) or
reminder systems. Interventions to improve TB treatment adherence must address a host of complex and
interacting barriers and facilitators. This assessment was based on nine core reviews, one relating to direct
effects [90] and eight relating to indirect effects [91–98]. M’IMUNYA et al. [90] reviewed studies of patient
education and counselling for promoting adherence to TB treatment, finding three trials which reported
LTBI treatment completion rates (children in Spain, adolescents in the USA, and prisoners in the USA).
Although incidence of active TB was a stated outcome of the review, no studies were identified which
measured progression to active TB. There were two core reviews of DOT [91, 97]. The Cochrane review
authors [91] concluded that there was insufficient evidence overall to either support or discount the
effectiveness of DOT in terms of TB treatment completion or cure, although only two out of 11 included
studies were set in high-income countries (USA and Australia). A core review of incentive-based
approaches [94] which included 10 studies from the USA (out of 12 included studies) found that material
incentives and enablers had: little or no effect in improving the outcomes of patients on treatment for
active TB; some effects on completion of prophylaxis for latent TB in some circumstances (but trial results
were mixed); and some positive short-term effects on clinic attendance for diagnostic test results and
prophylaxis, particularly for marginal populations such as drug users, recently released prisoners and the
homeless, but insufficient evidence to know if they can improve long-term adherence to TB treatment.
MDR-TB
Pooled analysis indicates overall treatment success rates of 26% and 60% for extensively drug-resistant
(XDR)- and MDR-TB patients, respectively [139]. No core reviews were found in relation to approaches to
MDR-TB treatment (e.g. drug regimens). Some of the supplementary reviews of drug regimens made
specific recommendations, e.g. linezolid for the treatment of XDR-TB or fluoroquinolone-resistant
MDR-TB [135] and six- and four-drug combinations in the intensive and continuation phases of XDR-TB
treatment [141], but the common conclusion was the urgent need for more RCTs of MDR- and XDR-TB
treatments. Three core reviews were identified in relation to preventive treatments for contacts of MDR-TB
cases, two of which found no evidence of effectiveness [130, 132]; a third was focused on adverse events,
finding no evidence of these [131]. Overall, there is insufficient review level evidence for effects of
interventions on MDR-TB incidence in MDR-TB cases or contacts.
Contacts and transmission
No core reviews were identified, and there is insufficient review level evidence from supplementary reviews
for specific interventions to improve contact investigation, in terms of direct or indirect effects on TB
incidence. The supplementary reviews recommend pragmatic actions such as investigating contacts of
MDR-TB cases, and LTBI treatment for child or HIV-positive contacts of active TB cases [152, 154–156], or
describing potential benefits of whole genome sequencing to support epidemiological investigations [151,
153]. Two reviews of TB in relation to air travel indicated a low risk of transmission in airplanes [157, 159].
Healthcare-associated infection
There is insufficient review level evidence for TB-specific interventions for HCWs or infection control in
healthcare settings, although this reflects a lack of systematic reviews in this area particularly in high-income
countries. There were three supplementary reviews on TB screening in HCWs [164–166]. LAMBERTI et al.
[164] concluded that, in the absence of a gold-standard test, TB surveillance in HCWs needed to consider
factors such as vaccination status, age and role, whilst ZWERLING et al. [166] commented that use of IGRAs
for serial testing in HCWs is complicated by lack of data on optimum cut-offs. Two supplementary reviews
analysed clinical prediction rules for respiratory isolation of patients with presumptive pulmonary TB [162,
163], both reviews indicated that clinical prediction rules tend to have high sensitivity but low specificity,
with inconclusive evidence for their utility in low TB-incidence settings.
Social support and vulnerable groups
There is insufficient review level evidence to support or discount the effectiveness of TB-specific social
support interventions or interventions in vulnerable groups. One core review by HEUVELINGS et al. [171]
was identified, which reviewed a wide range of interventions for diagnosis and treatment of TB in
hard-to-reach populations. This review extended and updated two earlier reviews by the UK National
Institute for Health and Care Excellence (NICE) [202, 203]. Of the 44 included primary studies, three had
reduction of TB incidence or number of TB cases prevented as outcomes; two of these studies were
included in other systematic reviews that we have reviewed under “screening”. The remaining study was a
non-randomised study of a social and healthcare programme for homeless people in Spain which reported
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pre-/post-intervention TB incidence compared with a non-intervention area as an outcome, but no reliable
conclusion could be drawn regarding the programme’s effectiveness [204]. A core review of psychosocial
and socioeconomic support found that these appeared to improve treatment outcomes across a variety of
settings and patient populations, but the authors rated the quality of the primary studies as very low [173].
Healthcare systems
There is insufficient review level evidence to support or discount the effectiveness of TB-specific
interventions at the level of healthcare systems in high-/low-incidence countries. Four of the five
supplementary reviews focused mainly on healthcare system interventions in low and middle-income
countries, including mixed public–private approaches [177], task-shifting (e.g. of treatment supervision to
community health workers, laypersons or family [178]), scaling-up of TB interventions such as isoniazid
preventive therapy, clinical algorithms and second-line treatment [176], and best practice in evaluating
specialist HCW training [179]. The fifth supplementary review comprised six separate reviews
commissioned to inform UK NICE guidelines for TB [175], including a review of information and
education interventions for service providers which concluded that intensive interventions integrating
clinician education with other components such as reminders, process improvement and incentives could
be effective in improving service delivery outcomes, particularly TB screening.
Pregnancy
There is insufficient review level evidence for direct or indirect effects of specific interventions relating to
TB during pregnancy. One supplementary review of 35 non-randomised studies included two which
investigated treatment of LTBI with INH during pregnancy (neither reported progression to active TB as
an outcome), 14 reported treatment of active TB and four reported treatment of MDR-TB [182]. The
authors highlighted delays in diagnosing and treating TB during pregnancy, poor adherence to INH
preventive therapy (and a possible elevated risk of INH toxic hepatitis), but the reviewed studies showed
no association between child abnormality and mother’s exposure to first- or second-line anti-TB drugs.
Prisons
TB incidence is often higher in correctional facilities than in the general population, but beyond standard
TB diagnosis and treatment procedures and infection control measures, there is insufficient review level
evidence for specific interventions in the context of prisons. One supplementary review of studies of INH
preventive therapy in prisons identified four studies which reported TB incidence as an outcome [188].
The review was of very low quality, and no conclusion could be drawn regarding the effectiveness of LTBI
treatment regimens in prison settings. A supplementary review identified limited accuracy of diagnostic
algorithms and lack of adequate laboratory facilities as key limitations for TB control programmes in
prisons [189].
Environment and behaviours
Whilst plausible associations of smoking and heavy alcohol consumption and, to a lesser extent,
second-hand tobacco smoke and indoor air pollution with TB were supported by a number of reviews
[191–201], there is as yet no review level evidence to support either the incorporation of smoking- or
alcohol-related interventions into programmes for TB control and prevention or to address these factors in
relation to treatment outcomes.
Discussion
Our review focused on interventions for which reduction in TB incidence and prevention of TB cases was
a directly measurable outcome, or could be inferred indirectly from another reported outcome, based on
evidence from systematic reviews. Clearly, we recognise the basic obligation to provide TB patients with
high-quality evidence-based clinical care that reduces suffering and mortality, and to make this standard of
care accessible to everyone. From this point of departure, our review identified two interventions
supported by sufficient review level evidence of direct effects in reducing TB incidence and preventing TB
cases, namely BCG vaccination and treatment of LTBI to prevent progression to active TB.
The insufficient review level evidence of direct effects in other intervention areas is a consequence of two
related factors: 1) the lack of good quality primary studies; and 2) the lack of good quality systematic
reviews. The first of these may be because policymakers perceive no added value in testing interventions
which, by simple logic, should have a beneficial impact (or where effectiveness, e.g. of drug regimens for
uncomplicated TB, is not disputed). Such testing may be unethical or would require RCTs of complex
interventions at large enough scale and of sufficient duration to detect an effect on TB incidence. The
second factor follows from the first or, where experimental evidence is available, reflects the difficulty of
synthesising evidence with substantial heterogeneity in settings, interventions and outcomes. In the
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absence of a comprehensive, consistent and robust review level evidence base, the choice of interventions
for TB control plans and programmes will continue to be pragmatic, at best supported by evidence from
individual studies, but otherwise based on local TB epidemiology, expert opinion and accumulated
national and international experience.
One of the main challenges to building an evidence base in TB control and prevention at national level is
the interconnectedness of interventions along the “cascade of care” from detection of TB through to
successful completion of treatment [181]. This implies that interventions need to be evaluated in a
joined-up rather than standalone manner. Also, the biggest impact on TB incidence over time has come
from societal, socioeconomic and wider healthcare improvements, which are beyond the remit of a TB
control plan. These changing factors, together with non-static populations, preclude before-and-after
studies as an unbiased method for evaluating TB-specific interventions [205]. Without substantial
investment to strengthen the evidence base, the pragmatic alternative is to accept that “good” interventions
may not be supported by “hard” evidence, and to trust that implementing a range of common-sense
interventions, alongside population-level improvements in social determinants and risk factors and
continual improvements in the effectiveness and quality of clinical care, will eventually lead to elimination
of TB. A persuasive counter-argument can be made that interventions deemed to be “good” even by the
application of logic may not be as effective as thought, or could be made more effective, hence why more
investment in research is essential. This research may require methodological innovation, such as using a
factorial trial design to add interventions, e.g. screening and reminder systems, to an optimised
programme of diagnosis and treatment, and measuring transmission (using molecular methods) as an
outcome [206].
Our findings in context
Vaccination
We reported sufficient evidence of protection against TB by BCG vaccination from four reviews. These
indicate that an important role remains for vaccination targeted at high-risk groups who are most likely to
benefit because of higher risk of exposure, with recent research suggesting >15 years’ duration of
protection by BCG [207, 208]. Although RCT evidence for the use of BCG in high-risk groups is unlikely
to be forthcoming for ethical reasons, TB control programmes should probably adopt this approach whilst
the search for a new and more effective TB vaccine continues [209].
Diagnosis and treatment
Perhaps unsurprisingly, these two areas accounted for the highest number of high-quality core reviews (21
out of 45 core reviews in total; eight in diagnostics, 13 in treatment). This reflects the relative ease with
which comparative clinical studies of diagnostic methods and treatment regimens can be designed,
conducted and systematically reviewed, compared with evaluations of complex interventions. Clinical
studies tend to capture outcomes such as treatment success and diagnostic accuracy, hence the majority
were categorised as having indirect effects on TB incidence that were not quantified as an outcome of the
included systematic review. Translating outcomes such as treatment efficacy into effects on TB incidence is
an area where modelling can be of some use [210]. That we found review level evidence for direct effects
on TB incidence of LTBI treatment and indirect effects of DST and sub-optimal treatment highlights the
importance of continuing to build a high-quality evidence base to support best practice in clinical care,
and of continuing to develop more accurate diagnostic tests and more efficacious and safer drugs.
Screening and LTBI
We found that evidence for the efficacy of LTBI treatment in contacts and persons with certain
comorbidities is robust, whilst evidence for LTBI screening, especially population-based programmes, is
much weaker. This lack of evidence is particularly important in view of south–north migration [211–214].
The recent push towards TB elimination in low-incidence countries in keeping with the ambitious End TB
Strategy has increased interest in systematic LTBI screening and treatment, because most TB disease in
these countries is a result of LTBI reactivation. It is worth noting that WHO issued strong
recommendations for LTBI treatment of persons with certain comorbidities, such as underlying
immunosuppressive diseases or medications, whilst only issuing conditional recommendations for wider
screening of migrants from high-incidence countries [215]. The trade-off and tension between provision of
LTBI treatment to only a few high-risk patients who have high likelihood of individual benefit from
treatment, but with little or no effect on country-level incidence, versus provision of screening to a larger
group at lower risk (such as migrants) with lower expected individual benefit but higher likelihood of
reducing population-level incidence, remains unresolved. Ultimately, national TB strategic planning must
base decisions about screening programmes on context, cost considerations and local TB epidemiology,
including the rate of MDR TB, for which LTBI treatment is still in its infancy.
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Adherence
Many variants on interventions to improve treatment adherence have been evaluated, particularly in
higher TB burden settings. Recent WHO guidelines [216] recommend that treatment should be based on
an assessment of individual patients’ needs, providers’ resources and conditions for implementation. The
paucity of review level evidence for direct effects on reducing the incidence of active TB in low-incidence
countries suggests the need for evaluation studies that can account for the complex and intersecting
determinants of poor adherence, which can vary both within an individual and over the course of
treatment. Under the auspices of the End TB Strategy there is a need to intensify efforts to design and test
public health interventions that explicitly target modifiable social and behavioural determinants of
adherence, thereby supporting high-risk groups in accessing and engaging with patient-centred care.
Strengths and limitations
The main strength of our study is the consistent methodology applied to all reviewed systematic reviews,
covering a wide range of interventions. We applied rigorous quality assessment criteria, the results of which
are consistent with an earlier assessment of the quality of systematic reviews on TB [217]. The main limitation
of a “review of reviews” approach is that evidence from primary studies will not be assessed if those studies
have not been systematically reviewed. Where studies have been reviewed, some “detail” may be lost because
we are synthesising evidence which has already been synthesised. We did report some pertinent details from
individual studies included in systematic reviews, where these primary studies provided the only evidence for a
particular intervention, but unreplicated single-study evidence must be interpreted with caution. It has also
been argued that systematic reviews may fail to capture effects of complex interventions, such as DOT,
particularly where simplified outcome measures are used [218]. This is an area where qualitative systematic
reviews could potentially contribute to evidence of effectiveness. Where we found sufficient evidence for
effects of interventions on TB incidence, we did not attempt to quantify the magnitude of these effects. For
example, BCG vaccination of infants in high-risk groups will have little impact on overall TB incidence and
case numbers in low-incidence countries because children represent a small proportion of TB cases. As a
public health intervention in low-incidence countries, BCG will be more effective in preventing
life-threatening paediatric TB cases, e.g. meningitis, than in reducing overall TB incidence.
Implications of our findings for TB control plans and strategies
The objective of our review was to synthesise an evidence base for the effectiveness of interventions for TB
control and prevention in low-incidence settings. Our aim was to use this evidence to inform the development
of a TB Strategy Toolkit for EU/EEA countries, which will include guidance on the prioritisation of
interventions within national TB control plans. The toolkit will be developed through a consensus approach,
incorporating other types of evidence including a survey of current practices and priorities in EU/EEA
countries [6], qualitative reviews of barriers and enablers to TB control [219, 220], current international
standards, and WHO and ECDC guidelines [221]. This consensus process will address questions such as how
to link national TB plans, which need to focus on strategic choices around interventions to reduce the overall
burden of TB in the population, with continually evolving guidelines and evidence around best practice in TB
patient care. Our review has shown the need for more evidence to support expert opinion and to support local
experience when making policy decisions in TB control and prevention.
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